Focused On-demand Library for DNA-directed RNA polymerase III subunit RPC8

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y535

UPID:

RPC8_HUMAN

Alternative names:

DNA-directed RNA polymerase III subunit H; RNA polymerase III subunit 22.9 kDa subunit

Alternative UPACC:

Q9Y535; B0QYH9; Q5M7Y8; Q96AE3; Q9BY95

Background:

DNA-directed RNA polymerase III subunit RPC8, also known as the 22.9 kDa subunit, plays a pivotal role in the transcription of DNA into RNA, utilizing ribonucleoside triphosphates. It is a specific component of RNA polymerase III, responsible for synthesizing small RNAs like 5S rRNA and tRNAs. This protein is crucial in the innate immune response, sensing and responding to intracellular bacteria and DNA viruses by detecting non-self dsDNA.

Therapeutic significance:

Understanding the role of DNA-directed RNA polymerase III subunit RPC8 could open doors to potential therapeutic strategies. Its involvement in the innate immune response highlights its potential as a target for modulating immune responses against infections and possibly autoimmune diseases.